Stockwatch: New Year, New Politics; Same Old Pricing And Generic Challenges
And Amarin Rallies Despite Unpromising Prospects
A positive start to the year for healthcare stocks was accompanied, as usual, by drug price increases. This and the other issues that have been carried over from 2020 remain just as challenging.
You may also be interested in...
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.
Deals announced by Sanofi and Novartis at this year’s virtual J.P. Morgan Healthcare Conference and a smattering of full-year revenue preannouncements did not mark a bumper start to the year.
Agios’s divestment of its oncology pipeline and commercial operations provided a rare case where all parties appeared satisfied. In many other cases, there are winners and losers.